enVVeno Medical Corporation Announces Pricing of $15.0 Million Public OfferingenVVeno Medical (NASDAQ:NVNO) has announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock (or pre-funded warrants) at $3.50 per share. The company expects to receive gross proceeds of approximately $15.0 millionfrom the offering, excluding underwriting discounts and other expenses. The offering is expected to close around September 30, 2024.
The company plans to use the net proceeds for the continued development of its two lead products, VenoValve and enVVe, and for general corporate purposes. Titan Partners Group is acting as the sole bookrunner for the offering. enVVeno has granted the underwriter a 30-day option to purchase up to an additional 642,857 shares at the public offering price.
MARKET-TEST-DUMMY : Any opinions about the offering?
Jaguar8 OP MARKET-TEST-DUMMY : It’s priced 3.50/sh so it may reach that price depending still on market sentiment. Sometimes even if there is dilution news, stock price still goes up but generally it goes down.
MARKET-TEST-DUMMY Jaguar8 OP : Ya, kinda what I was thinking
MARKET-TEST-DUMMY MARKET-TEST-DUMMY : 50/50